A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis

Phase 4 Completed 100 enrolled Johnson & Johnson Private Limited

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety of subcutaneous (SC) golimumab in participants with active Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) over 24 weeks.

Timeline

Start: 2019-01-07
Primary completion: 2021-11-15
Completion: 2021-11-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Golimumab	Monoclonal antibody	50 mg	Subcutaneous

A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis

Summary

Timeline

Drugs

Indications